ABI to Accelerate Launch of Sequencer, Posts 7 Percent Revenue Gain for Q4
 
Applied Biosystems this week said that it is accelerating by at least three months the formal launch of its SOLiD next-generation DNA sequencer.
 
The company also said that fiscal fourth-quarter revenues rose 7 percent as R&D spending surged 15.6 percent and profit grew 14.5 percent. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.